MYGN - Myriad Genetics, Inc.
NASDAQ
->
Healthcare
->
Diagnostics & Research
Salt Lake City,
United States
Type: Equity
MYGN price evolution
MYGN
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $132.1 | $76 | $102.8 | $53.6 |
| Short term investments | $8.8 | $10.3 | $18.8 | $25.1 |
| Net receivables | $114.3 | $115.2 | $111.7 | $119.1 |
| Inventory | $22 | $25.1 | $22.5 | $21.8 |
| Total current assets | $313.6 | $265.4 | $294.3 | $261.6 |
| Long term investments | $6.2 | $30.4 | ||
| Property, plant & equipment | $180.6 | $224.7 | $218.6 | $203.3 |
| Goodwill & intangible assets | $636.9 | $643.2 | $646 | $656.5 |
| Total noncurrent assets | $832.9 | $883.7 | $892.9 | $907.7 |
| Total investments | $8.8 | $10.3 | $25 | $55.5 |
| Total assets | $1146.5 | $1149.1 | $1187.2 | $1169.3 |
| Current liabilities | ||||
| Accounts payable | $25.8 | $33.9 | $39.8 | $36.5 |
| Deferred revenue | ||||
| Short long term debt | $16.2 | $17.8 | $17 | $15.1 |
| Total current liabilities | $155.9 | $209.3 | $221.1 | $143.3 |
| Long term debt | $135.9 | $183.6 | $186.8 | $146.5 |
| Total noncurrent liabilities | $207.4 | $256.4 | $230.9 | $190.8 |
| Total debt | $152.1 | $201.4 | $203.8 | $161.6 |
| Total liabilities | $363.3 | $465.7 | $452 | $334.1 |
| Shareholders' equity | ||||
| Retained earnings | -$629.5 | -$598.3 | -$537 | -$420.9 |
| Other shareholder equity | -$3.7 | -$5.3 | -$5.4 | -$7.4 |
| Total shareholder equity | $783.2 | $683.4 | $735.2 | $835.2 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $132.1 | $53.6 | $258.4 | $163.7 |
| Short term investments | $8.8 | $58 | $81.4 | $54.1 |
| Net receivables | $114.3 | $101.6 | $91.3 | $71 |
| Inventory | $22 | $20.1 | $15.3 | $29.1 |
| Total current assets | $313.6 | $274.6 | $484.8 | $331.7 |
| Long term investments | $54.8 | $59 | $37 | |
| Property, plant & equipment | $180.6 | $187.3 | $125.3 | $103 |
| Goodwill & intangible assets | $636.9 | $666.5 | $643.3 | $932.9 |
| Total noncurrent assets | $832.9 | $924.1 | $835.9 | $1072.9 |
| Total investments | $8.8 | $112.8 | $140.4 | $91.1 |
| Total assets | $1146.5 | $1198.7 | $1320.7 | $1404.6 |
| Current liabilities | ||||
| Accounts payable | $25.8 | $28.8 | $29.6 | $21.7 |
| Deferred revenue | $5.2 | $32.8 | ||
| Short long term debt | $16.2 | $14.1 | $13 | $13.5 |
| Total current liabilities | $155.9 | $137.2 | $204.3 | $147 |
| Long term debt | $135.9 | $130.9 | $79.3 | $281.3 |
| Total noncurrent liabilities | $207.4 | $175.7 | $148.6 | $339.4 |
| Total debt | $152.1 | $145 | $92.3 | $294.8 |
| Total liabilities | $363.3 | $312.9 | $352.9 | $486.4 |
| Shareholders' equity | ||||
| Retained earnings | -$629.5 | -$366.2 | -$254.2 | -$173.9 |
| Other shareholder equity | -$3.7 | -$8.9 | -$5.1 | -$5.2 |
| Total shareholder equity | $783.2 | $885.8 | $967.8 | $918.2 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $196.6 | $191.9 | $183.5 | $181.2 |
| Cost of revenue | $61.6 | $57.6 | $57.8 | $59.2 |
| Gross Profit | $135 | $134.3 | $125.7 | $122 |
| Operating activities | ||||
| Research & development | $21 | $24 | $21.2 | $22.5 |
| Selling, general & administrative | $144.4 | $136.1 | $140.7 | $151.7 |
| Total operating expenses | $166.4 | $194.4 | $239.4 | $174.2 |
| Operating income | -$31.4 | -$60.1 | -$113.7 | -$52.2 |
| Income from continuing operations | ||||
| EBIT | -$31.4 | -$60.2 | -$115.6 | -$52.1 |
| Income tax expense | -$1.1 | $0.1 | $2.1 | |
| Interest expense | $0.9 | $1 | $0.5 | $0.5 |
| Net income | ||||
| Net income | -$31.2 | -$61.3 | -$116.1 | -$54.7 |
| Income (for common shares) | -$31.2 | -$61.3 | -$116.1 | -$54.7 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $753.2 | $678.4 | $690.6 | $638.6 |
| Cost of revenue | $236.2 | $202 | $197.6 | $186.1 |
| Gross Profit | $517 | $476.4 | $493 | $452.5 |
| Operating activities | ||||
| Research & development | $88.7 | $85.4 | $81.9 | $77.2 |
| Selling, general & administrative | $572.9 | $514.7 | $537.8 | $510.1 |
| Total operating expenses | $774.4 | $617 | $683.5 | $687 |
| Operating income | -$257.4 | -$140.6 | -$190.5 | -$234.5 |
| Income from continuing operations | ||||
| EBIT | -$259.3 | -$137.4 | -$50.5 | -$212.4 |
| Income tax expense | $1.1 | -$28.6 | -$29.9 | -$23.7 |
| Interest expense | $2.9 | $3.2 | $6.6 | $10.8 |
| Net income | ||||
| Net income | -$263.3 | -$112 | -$27.2 | -$199.5 |
| Income (for common shares) | -$263.3 | -$112 | -$27.2 | -$199.5 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$31.2 | -$61.3 | -$116.1 | -$54.7 |
| Operating activities | ||||
| Depreciation | $17.8 | $16.9 | $16.2 | $22.3 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $10.4 | $11.6 | $11.2 | $7.5 |
| Total cash flows from operations | -$54.7 | -$22.1 | -$0.9 | -$33.2 |
| Investing activities | ||||
| Capital expenditures | -$13.5 | -$17.5 | -$18.8 | -$23.5 |
| Investments | $1.5 | $15 | $30.6 | $58.1 |
| Total cash flows from investing | -$12 | -$2.5 | $11.8 | $34.6 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $123.6 | |||
| Net borrowings | -$0.2 | -$0.3 | $38.6 | |
| Total cash flows from financing | $121.9 | -$2.5 | $38.4 | -$4.9 |
| Effect of exchange rate | $0.7 | -$0.6 | $0.3 | $0.2 |
| Change in cash and equivalents | $55.9 | -$27.7 | $49.6 | -$3.3 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$263.3 | -$112 | -$27.2 | -$199.5 |
| Operating activities | ||||
| Depreciation | $73.2 | $64.4 | $75.6 | $72 |
| Business acquisitions & disposals | -$57.2 | $379.1 | $21.3 | |
| Stock-based compensation | $40.7 | $38.1 | $36.3 | $25.2 |
| Total cash flows from operations | -$110.9 | -$106.3 | $18.2 | $60.7 |
| Investing activities | ||||
| Capital expenditures | -$73.3 | -$45.3 | -$18 | -$10.2 |
| Investments | $105.2 | $25 | -$86.7 | $8.2 |
| Total cash flows from investing | $31.9 | -$77.5 | $274.4 | $19.3 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $123.6 | $6.3 | $91.8 | $3.5 |
| Net borrowings | $38.1 | -$0.7 | -$227.6 | -$9.6 |
| Total cash flows from financing | $152.9 | -$8 | -$150.6 | -$10 |
| Effect of exchange rate | $0.6 | -$0.6 | -$0.6 | $0.5 |
| Change in cash and equivalents | $74.5 | -$192.4 | $141.4 | $70.5 |
News
Fundamentals
| Market cap | $1.66B |
|---|---|
| Enterprise value | $1.68B |
| Shares outstanding | 89.90M |
| Revenue | $753.20M |
|---|---|
| EBITDA | -$186.10M |
| EBIT | -$259.30M |
| Net Income | -$263.30M |
| Revenue Q/Q | 10.57% |
| Revenue Y/Y | 11.03% |
| P/E ratio | -6.32 |
|---|---|
| EV/Sales | 2.24 |
| EV/EBITDA | -9.05 |
| EV/EBIT | -6.49 |
| P/S ratio | 2.21 |
| P/B ratio | 2.11 |
| Book/Share | 8.75 |
| Cash/Share | 1.47 |
| EPS | -$2.93 |
|---|---|
| ROA | -22.64% |
| ROE | -34.68% |
| Debt/Equity | 0.46 |
|---|---|
| Net debt/EBITDA | -1.24 |
| Current ratio | 2.01 |
| Quick ratio | 1.87 |